মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →এই ওষুধে সাশ্রয় করুন
একই সক্রিয় উপাদান — 12% পর্যন্ত কম দিন
এই ব্র্যান্ডগুলোতে একই সক্রিয় উপাদান আছে (Ertugliflozin). একই মাত্রা ও ধরন। বদলানোর আগে আপনার ডাক্তার বা ফার্মাসিস্টের সাথে নিশ্চিত হয়ে নিন।
ইঙ্গিত ও ব্যবহার
Ertoxa এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Dosage The recommended starting dose of Ertugliflozin is 5 mg once daily, taken in the morning, with or without food. In patients tolerating Ertugliflozin 5 mg once daily, the dose may be increased to a maximum recommended dose of 15 mg once daily if additional glycemic control is needed.Patients with renal impairment- Assess renal function prior to initiation of Ertugliflozin and periodically thereafter Use of Ertugliflozin is contraindicated in patients with an eGFR less than 30 mL/minute/1.73 m2 Initiation of Ertugliflozin is not recommended in patients with an eGFR of 30 mL/minute/1.73 m2 to less than 60 mL/minute/1.73 m2 Continued use of Ertugliflozin is not recommended when eGFR is persistently between 30 and less than 60 mL/minute/1.73 m2. Hepatic impairment: No dose adjustment of ertugliflozin is necessary in patients with mild or moderate hepatic impairment. Ertugliflozin has not been studied in patients with severe hepatic impairment and is not recommended for use in these patients. Pediatric population: The safety and efficacy of ertugliflozin in children under 18 years of age have not been established. No data are available.
পার্শ্বপ্রতিক্রিয়া
Side effects may include: cough (with or without phlegm), stuffy or runny nose, sore throat, mouth ulcers, diarrhea, nausea and vomiting, abdominal pain, constipation, weight loss, headache/dizziness, back pain joint pain, muscle pain, feeling weak, tremor etc.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Ketoacidosis: Reports of ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, have been identified in clinical trials and post marketing surveillance in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose co-transporter-2 (SGLT2) inhibitors and cases have been reported in Ertuglif treated patients in clinical trials. Across the clinical program, ketoacidosis was identified in 3 of 3,409 (0.1%) of Ertuglif treated patients and 0% of comparator-treated patients. Fatal cases ofketoacidosis have been reported in patients taking SGLT2 inhibitors. Patients treated with Ertuglif who present with signs and symptoms consistent with severe metabolic acidosis should be assessed for ketoacidosis regardless of presenting blood glucose levels, as ketoacidosis associated with Ertuglif may be present even if blood glucose levels are less than 250 mg/dL. If ketoacidosis is suspected, Ertuglif should be discontinued, patient should be evaluated, and prompt treatment should be instituted. Treatment of ketoacidosis may require insulin, fluid and carbohydrate replacement.General: Ertuglif is not indicated for the treatment of patients with type 1 diabetes mellitus.Hypotension: Ertuglif causes intravascular volume contraction. Therefore, symptomatic hypotension may occur after initiating Ertuglif particularly in patients with impaired renal function (eGFR less than 60mL/min/1.73 m2) [see Use In Specific Populations], elderly patients (>65 years), in patients with low systolic blood pressure, and in patients on diuretics. Before initiating Ertuglif, volume status should be assessed and corrected if indicated. Monitor for signs and symptoms of hypotension after initiating therapy.Acute Kidney Injury And Impairment In Renal Function: Ertuglif causes intravascular volume contraction and can cause renal impairment. There have been post marketing reports of acute kidney injury some requiring hospitalization and dialysis in patients receiving SGLT2 inhibitors. Before initiating Ertuglif, consider factors that may predispose patients to acute kidney injury including hypovolemia, chronic renal insufficiency, congestive heart failure and concomitant medications (diuretics, ACE inhibitors, ARBs, NSAIDs). Consider temporarily discontinuing Ertuglif in any setting of reduced oral intake (such as acute illness or fasting) or fluid losses (such as gastrointestinal illness or excessive heat exposure); monitor patients for signs and symptoms of acute kidney injury. If acute kidney injury occurs, discontinue Ertuglif promptly and institute treatment. Ertuglif increases serum creatinine and decreases eGFR. Patients with moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m2) may be more susceptible to these changes. Renal function abnormalities can occur after initiating Ertuglif. Renal function should be evaluated prior to initiating Ertuglif and periodically thereafter. Use of Ertuglif is not recommended when eGFR ispersistently between 30 and less than 60 mL/min/1.73 m2 and is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2 Hypoglycemia With Concomitant Use With Insulin And Insulin SecretogoguesInsulin and insulin secretogogues (e.g., sulfonylurea) are known to cause hypoglycemia. Ertuglif may increase the risk of hypoglycemia when used in combination with insulin and/or an insulin secretogogue. Therefore, a lower dose of insulin or insulin secretogogue may be required to minimize the risk of hypoglycemia when used in combination with Ertuglif.Increases In Low-Density Lipoprotein Cholesterol (LDL-C): Dose-related increases in LDL-C can occur with Ertuglif. Monitor and treat as appropriate.Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Ertuglif.
নিষেধাজ্ঞা
Severe renal impairment, end-stage renal disease (ESRD), or dialysis. History of a serious hypersensitivity reaction to Ertugliflozin.